Literature DB >> 19386438

Margin on gross tumor volume and risk of local recurrence in head-and-neck cancer.

Jimmy J Caudell1, Ruby F Meredith, Sharon A Spencer, Kimberley S Keene, M Christian Dobelbower, James A Bonner.   

Abstract

PURPOSE: To determine whether the method or extent of construction of the high-dose clinical target volume (CTV) and high-dose planning target volume (PTV) in intensity-modulated radiation therapy (IMRT) for head-and-neck cancer are associated with an increased risk of locoregional failure.
MATERIALS AND METHODS: Patients with nasopharyngeal, oropharyngeal, oral cavity, hypopharyngeal, or laryngeal squamous cell carcinomas treated definitively with IMRT were included. All patients without local relapse had a minimum follow-up of 12 months. Median follow-up for all patients was 24 months. Treatment plans of 85 available patients were reviewed, and the gross tumor volume (GTV) to PTV expansion method was estimated.
RESULTS: The GTVs were expanded volumetrically in 71 of 85 patients, by a median of 15 mm (range, 4-25 mm). An anatomic component to the expansion of GTV was used in 14 of 85 patients. Eighteen patients failed locoregionally, for an actuarial locoregional control rate of 77.2% at 2 years. There was no significant difference in locoregional control between patients with GTVs expanded volumetrically vs. those with a component of anatomic expansion. In patients with GTVs expanded volumetrically, no increase in risk of local failure was seen in patients with a total GTV expansion of < or =15 mm.
CONCLUSION: In this retrospective study, there was not an increased risk of local failure using smaller margins or expanding GTVs volumetrically when treating head-and-neck cancer patients definitively with IMRT.

Entities:  

Mesh:

Year:  2010        PMID: 19386438     DOI: 10.1016/j.ijrobp.2009.01.037

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  13 in total

1.  Disease course after the first recurrence of head and neck squamous cell carcinoma following (chemo)radiation.

Authors:  Mischa de Ridder; Pieter D de Veij Mestdagh; Joris B W Elbers; Arash Navran; Charlotte L Zuur; Ludi E Smeele; Abrahim Al-Mamgani
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-10-10       Impact factor: 2.503

2.  Clinical outcomes for larynx patients with cancer treated with refinement of high-dose radiation treatment volumes.

Authors:  Adam R Burr; Paul M Harari; Alyx M Haasl; Aaron M Wieland; Justine Y Bruce; Randall J Kimple; Gregory K Hartig; Timothy M McCulloch; Matthew E Witek
Journal:  Head Neck       Date:  2020-02-14       Impact factor: 3.147

3.  Reducing radiotherapy target volume expansion for patients with HPV-associated oropharyngeal cancer.

Authors:  Adam R Burr; Paul M Harari; Huaising C Ko; Justine Y Bruce; Randall J Kimple; Matthew E Witek
Journal:  Oral Oncol       Date:  2019-03-22       Impact factor: 5.337

4.  Recurrent oropharyngeal cancer after organ preserving treatment: pattern of failure and survival.

Authors:  M de Ridder; Z A R Gouw; J J Sonke; A Navran; B Jasperse; J Heukelom; M E T Tesselaar; W M C Klop; M W M van den Brekel; Abrahim Al-Mamgani
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-12-09       Impact factor: 2.503

5.  Dosimetric impact of target definitions on normal structures in head and neck cancer.

Authors:  Micah T Monaghan; James A Bonner; Philip E Schaner; Jimmy J Caudell
Journal:  Head Neck Oncol       Date:  2011-08-11

6.  DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer.

Authors:  Imran Petkar; Keith Rooney; Justin W G Roe; Joanne M Patterson; David Bernstein; Justine M Tyler; Marie A Emson; James P Morden; Kathrin Mertens; Elizabeth Miles; Matthew Beasley; Tom Roques; Shreerang A Bhide; Kate L Newbold; Kevin J Harrington; Emma Hall; Christopher M Nutting
Journal:  BMC Cancer       Date:  2016-10-06       Impact factor: 4.430

7.  Primary tumor volume delineation in head and neck cancer: missing the tip of the iceberg?

Authors:  Olgun Elicin; Dario Terribilini; Mohamed Shelan; Werner Volken; Etienne Mathier; Alan Dal Pra; Daniel M Aebersold; Michael K Fix; Peter Manser
Journal:  Radiat Oncol       Date:  2017-06-20       Impact factor: 3.481

8.  Comparative effectiveness trial of transoral head and neck surgery followed by adjuvant radio(chemo)therapy versus primary radiochemotherapy for oropharyngeal cancer (TopROC).

Authors:  Lara Bußmann; Simon Laban; Claus Wittekindt; Carmen Stromberger; Silke Tribius; Nikolaus Möckelmann; Arne Böttcher; Christian Stephan Betz; Jens Peter Klussmann; Volker Budach; Adrian Muenscher; Chia-Jung Busch
Journal:  BMC Cancer       Date:  2020-07-29       Impact factor: 4.430

9.  Local Failure Rate in Oropharyngeal Carcinoma Patients Treated with Intensity-modulated Radiotherapy Without High-dose Clinical Target Volume.

Authors:  Hatim Almarzouki; Tamim Niazi; Michael Hier; Alex Mlynarek; Isabelle Lavoie; Khalil Sultanem
Journal:  Cureus       Date:  2018-07-10

10.  The impact of reduced-volume, intensity-modulated radiation therapy on disease control in nasopharyngeal carcinoma.

Authors:  Yu-Wei Lin; Chia-Chun Chen; Li-Ching Lin; Steve P Lee
Journal:  PLoS One       Date:  2015-04-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.